Update on chronic hepatitis C in hemophiliacs

Haematologica

Volumn 87, Issue 5, 2002, Pages 542-549

  Franchini, Massimo ^a   Capra, Franco ^a   Tagliaferri, Annarita ^a   Rossetti, Gina ^a   De Gironcoli, Marzia ^a   Rocca, Paolo ^a   Aprili, Giuseppe ^a   Gandini, Giorgio ^a  

^a OSPEDALE POLICLINICO   (Italy)

Author keywords

HCV infection; Hemophilia; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR;

ARTICLE; BLOOD CLOTTING; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENOTYPE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MORBIDITY; MORTALITY; PREVALENCE; RISK FACTOR; TREATMENT PLANNING; CHRONIC DISEASE; HEMOPHILIA A; REVIEW; VIROLOGY;

CHRONIC DISEASE; DISEASE PROGRESSION; HEMOPHILIA A; HEPATITIS C; HUMANS; PREVALENCE; RISK FACTORS;

EID: 0036096392     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Management of hepatitis C in the hemophilia patient
2. Hepatitis C infection and its management
3. Liver disease in hemophilia
4. Hepatitis C antibody and chronic liver disease in haemophilia
5. A multicenter study of viral hepatitis in a United States hemophilic population
6. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: A retrospective evaluation
7. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
8. Hepatitis C virus and human immunodeficiency virus: Clinical issues in coinfection
9. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus (HIV). The Multicenter Hemophilia Cohort Study
10. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
11. The natural history of chronic hepatitis C in hemophiliacs
12. The progression of HCV-associated liver disease in a cohort of hemophilic patients
13. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985
14. Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders
15. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders
16. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients
17. Hepatitis C infection and viremia in Dutch hemophilia patients
18. Hepatitis C virus genotypes in multitransfused individuals
19. Hepatitis C virus infection in special groups
20. Hepatitis C virus infection in Western Europe
21. HCV genotypes in Northern Italy: A survey of 1368 histologically proven chronic hepatitis C patients
22. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States
23. Virological characteristics of HCV infection in Japanese haemophiliacs
24. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study
25. Chronic hepatitis C virus infection in haemophilic patients: Clinical significance of viral genotype
26. Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs
27. High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C
28. Heterogeneity of hepatitis C virus genotypes in hemophilia: Relationship with chronic liver disease
29. Natural history of hepatitis C
30. Why is there such difficulty in defining the natural history of hepatitis C?
31. Recovery, persistence, and sequelae ir hepatitis C virus infection: A perspective on long-term outcome
32. 45-Year follow-up of hepatitis C virus infection in healthy young adults
33. Pathogenesis, natural history, treatment, and prevention of hepatitis C
34. The natural history of hepatitis C virus infection: Host, viral, and environmental factors
35. Clinical outcomes after transfusion-associated hepatitis C
36. The natural history of hepatitis C
37. Prognosis of chronic hepatitis C: Results of a large prospective cohort study
38. Non-A, non-B post-transfusion hepatitis: Looking back in the second decade
39. The long-term pathological evolution of chronic hepatitis C
40. Incidence, character and clinical relevance of mixed cryoglobulinemia in patients with chronic hepatitis C virus infection
41. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-oc
42. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage
43. Clinical relevance of serum cryoglobulins in hemophilic patients with hepatitis C virus infection
44. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: Effects of prophylactic immune serum globulin
45. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs
46. Clinical significance of hepatitis C virus genotypes
47. Hepatocellular carcinoma in hemophilia
48. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C
49. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C
50. Investigation of chronic hepatitis C infection in individuals with haemophilia
51. Investigation of chronic hepatitis C infection in individuals with hemophilia: Assessment of invasive and non-invasive methods
52. A study of liver biopsies and liver disease among hemophiliacs
53. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus
54. Liver biopsy for haemophilic patients with chronic HCV infection
55. Liver biopsies in adult hemophiliacs with hepatitis C: A United States Center's experience
56. Mortality before and after HIV infection in the complete UK population of haemophiliacs
57. Progression of HIV in haemophilia
58. Hepatitis C virus infection
59. Transmission of hepatitis C virus - Route, dose, and titer
60. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use
61. Hepatitis C. alcohol
62. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
63. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
64. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
65. Randomised, double-blind, placebocontrolled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
66. Treatment of chronic hepatitis C in haemophilia patients
67. Interferon treatment for chronic hepatitis C infection in hemophiliacs: Influence of virus load, genotype, and liver pathology on response
68. Viral hepatitis and bleeding disorders
69. A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C
70. Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
71. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs
72. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs
73. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with α-2b interferon is not a predictor for sustained response to treatment
74. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C
75. Effect and side-effect of α-interferon treatment in haemophilia patients with chronic hepatitis C
76. Hepatitis C genotypes in haemophilic patients treated with α-interferon
77. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia
78. Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders
79. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus
80. Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups
81. Combined α interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders
82. A long-term follow-up study of interferon treatment for chronic hepatitis C in Japanese patients with congenital bleeding disorders
83. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan
84. An emerging role for interferon in haemophiliacs with chronic hepatitis C?
85. High-dose and long-term therapy of α-interferon in hemophiliac patients with chronic C virus hepatitis
86. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
87. Long-term outcome of hepatitis C infection after liver transplantation
88. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
89. Liver transplantation in a hemophiliac
90. Liver transplantation in hemophilia A
91. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome
92. Orthotopic liver transplantation in a patient with severe haemophilia A and with advanced liver cirrhosis
93. Outcome of orthotopic liver transplantation in patients with haemophilia
94. The hemophilias: From royal genes to gene therapy